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SPINK5, the Defective Gene in Netherton Syndrome,
Encodes Multiple LEKTI Isoforms Derived from
Alternative Pre-mRNA Processing
Alessandro Tartaglia-Polcini1,4, Chrystelle Bonnart2,4, Alessia Micheloni1, Francesca Cianfarani1,
Alessandra Andre`1, Giovanna Zambruno1, Alain Hovnanian2,3 and Marina D’Alessio1
The multidomain serine protease inhibitor lymphoepithelial Kazal-type related inhibitor (LEKTI) represents a
key regulator of the proteolytic events occurring during epidermal barrier formation and hair development, as
attested by the severe autosomal recessive ichthyosiform skin condition Netherton syndrome (NS) caused by
mutations in its encoding gene, serine protease inhibitor Kazal-type 5 (SPINK5). Synthesized as a proprotein,
LEKTI is rapidly cleaved intracellularly, thus generating a number of potentially bioactive fragments that are
secreted. Here, we show that SPINK5 generates three classes of transcripts encoding three different LEKTI
isoforms, which differ in their C-terminal portion. In addition to the previously described 15 domain isoform,
SPINK5 encodes a shorter LEKTI isoform composed of only the first 13 domains, as well as a longer isoform
carrying a 30-amino-acid residue insertion between the 13th and 14th inhibitory domains. We demonstrate that
variable amounts of SPINK5 alternative transcripts are detected in all SPINK5 transcriptionally active tissues.
Finally, we show that in differentiated cultured human keratinocytes all SPINK5 alternative transcripts are
translated into protein and that the LEKTI precursors generate distinct secreted C-terminal proteolytic
fragments from a similar cleavage site. Since several data indicate a biological role for the pro-LEKTI-cleaved
polypeptides, we hypothesize that the alternative processing of the SPINK5 pre-messenger RNA represents an
additional mechanism to further increase the structural and functional diversity of the LEKTI bioactive
fragments.
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INTRODUCTION
Proteases and their natural cognates, the protease inhibitors,
constitute a very large group of molecules that participate and
regulate a wide range of physiological reactions in cells and
tissues (Laskowski and Kato, 1980). Among them, the serine
protease inhibitor lymphoepithelial Kazal-type related in-
hibitor (LEKTI) is of special interest because of its pathophy-
siological importance. Defective expression of this molecule
causes the severe autosomal recessive skin disorder,
Netherton syndrome (NS, OMIM 266500) (Chavanas et al.,
2000a), which is characterized by ichthyosiform erythro-
derma, a specific hair shaft defect known as trichorrhexis
invaginata or bamboo hair, and atopic manifestations
(Come`l, 1949; Netherton, 1958).
Strongly expressed in the granular and uppermost spinous
layers of the epidermis and in the most differentiated layers of
all stratified epithelia (Bitoun et al., 2003), LEKTI has recently
been shown to represent a key regulator of epidermal
proteases involved in the barrier formation and its physiolo-
gical renewal. Indeed, LEKTI deficiency causes, both in
humans and mice, abnormal desmosome cleavage at the
granular layer–stratum corneum transition (Yang et al., 2004;
Descargues et al., 2005; Hewett et al., 2005; Ishida-
Yamamoto et al., 2005). This leads to defective stratum
corneum adhesion, which in turn, results in the loss of skin
barrier function, accounting for many of the NS clinical
features and complications, including bacterial infections as
well as failure to thrive (Yang et al., 2004; Descargues et al.,
2005; Hewett et al., 2005).
Kazal-type serine protease inhibitors comprise a family of
proteins defined by the presence of three conserved disulfide
bonds and a reactive site loop in each inhibitory domain
(Roberts et al., 1995). Named Kazal after the discoverer of the
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pancreatic secretory trypsin inhibitor, the prototype of this
family (Kazal et al., 1948), these proteins are usually
composed of only one inhibitory domain (Roberts et al.,
1995). However, in avian and other organisms, Kazal-type
serine protease inhibitors may contain up to seven inhi-
bitory domains with different target specificities (Johansson
et al., 1994; van de Locht et al., 1995; Saxena and Tayyab,
1997).
LEKTI, initially identified as the precursor protein of two
peptides isolated from human blood filtrate, was thought to
be a multidomain Kazal-type serine protease inhibitor
because of its structural relation with other inhibitors of this
family (Magert et al., 1999). However, LEKTI, as deduced
from the nucleotide (nt) sequence of the cloned B3.5 kb
complementary DNA (cDNA) (GenBank NM_006846), here-
in named serine protease inhibitor Kazal-type 5 full-length
(SPINK5f-l), is a large polypeptide (1,064 amino acids) that
contains as many as 15 potential inhibitory domains
(D1–D15), preceded by a signal peptide (Magert et al.,
1999). Only two of the inhibitory domains, D2 and D15,
match the typical Kazal motif with six cystein residues at
fixed positions, while the other 13 domains exhibit a Kazal-
type-derived four cystein residue pattern. Since some
proteolytic fragments of LEKTI have been detected in human
blood (Magert et al., 1999; Ahmed et al., 2001), cultured
epidermal keratinocytes (Bitoun et al., 2003), and human hair
roots (Raghunath et al., 2004), full-length LEKTI (LEKTIf-l) is
thought to be a proprotein, the proteolytic process of which
would generate a number of biologically active fragments.
Moreover, the demonstration of an LEKTIf-l recombinant
protein inhibitory activity versus a battery of natural proteases
such as plasmin, trypsin, subtilisin A, cathepsin G, and
elastase suggests a multiple inhibitory function for LEKTI
(Magert et al., 2002; Mitsudo et al., 2003; Jayakumar et al.,
2004; Kreutzmann et al., 2004). To date, the nature of the
LEKTI targets is still uncertain. The recent characterization of
Spink5 null mice has shown that LEKTI plays a crucial role in
epidermal desquamation, keratinization, barrier formation,
and hair morphogenesis, and has also allowed the identifica-
tion of the serine proteases stratum corneum tryptic enzyme
and stratum corneum chymotryptic enzyme as potential
LEKTI-interacting proteins (Yang et al., 2004; Descargues
et al., 2005; Hewett et al., 2005). However, the phenotype of
NS patients supports the involvement of LEKTI also in other
biological pathways relevant to inflammation and antimicro-
bial defense.
The human SPINK5 gene, which resides on chromosome 5
(5q32), is a single-copy gene composed of 33 exons
(Chavanas et al., 2000b). The encoded protein, LEKTIf-l, is
predicted to have a molecular weight of B120 kDa
(GeneBank Q9NQ38). However, we have recently reported
the detection of two LEKTI glycosylated precursors, a
B145 kDa full-length protein (LEKTIf-l) and a shorter isoform
of B125 kDa (LEKTI short, LEKTIsh) as well as of three
C-terminal fragments ofB68, 65, and 42 kDa, in differentiated
normal human keratinocytes (NHK) (Bitoun et al., 2003).
Here, we report the characterization and expression
analysis of two novel SPINK5 messenger RNAs (mRNAs) that
are generated by alternative processing of the SPINK5 pre-
mRNA. We also report the detection of a third B148 kDa
LEKTI precursor in NHKs, and formally demonstrate that the
B148, 145, and 125 kDa LEKTI precursors correspond to the
translation products of the three distinct SPINK5 mRNAs.
Finally, by transfecting the different cDNA forms into
mammalian cells, we validate the LEKTI proteolysis observed
in NHKs and demonstrate that the B65 and 42 kDa
proteolytic fragments detected in NHKs represent the
C-terminal portions of LEKTIf-l and LEKTIsh precursor forms,
respectively, generated from the use of the same cleavage site
present on both precursors.
RESULTS
Isolation of SPINK5 alternative transcripts
To date only aB3.5 kb SPINK5 transcript has been described
(Magert et al., 1999) (GenBank NM_006846). However, we
found evidence for the presence of two LEKTI precursors in
differentiated NHK (Bitoun et al., 2003). To investigate
whether this finding could be ascribed to the existence of
different SPINK5 mRNAs, a l phage cDNA library from
differentiated NHK was screened. Interestingly, sequence
analysis of the selected clones revealed the presence of two
novel SPINK5 mRNAs in addition to the published one. One
of them is a B3 kb polyadenylated transcript with an open
reading frame identical to the previously characterized
SPINK5f-l mRNA up to the lysine 913 codon (Figure 1a).
Thereafter, three novel in-frame codons (gtt-att-tat) are
followed by a termination codon TAA and a 91 bp
30untranslated region in which a potential polyadenylation
signal (AATAAA) is identifiable (Figure 1b). The second novel
mRNA, as compared to the full-length transcript, carries a
90 bp in-frame insertion between lysine 913 and aspartate
914 codons (Figure 1c).
To determine the mechanism underlying the production of
the novel SPINK5 mRNAs, a computer-based analysis of the
SPINK5 genomic sequences (GenBank NT_029289.10) was
carried out using the NCBI BLAST search program (http://
www.ncbi/blast.com). This analysis revealed that the full-
length and the shorter cDNA species diverge after the last nt
of exon 28 (GenBank NT_029289.10, nt 8,667,936) and that
the three in-frame additional codons and the 30untranslated
region portion of the shorter transcript correspond to the 50
portion of intron 28 in which a cryptic polyadenylation signal
and a GT-rich element are recognizable (GenBank
NT_029289.10, nts 8,667,937—8,221). As these motifs are
important for mRNA 30-end formation and cleavage (Birnstiel
et al., 1985), we concluded that the B3 kb transcript
represents an alternatively processed form of the SPINK5
pre-mRNA and was designated SPINK5sh (SPINK5 short)
(GenBank DQ149929).
For the third mRNA species, analysis of the SPINK5
genomic sequences revealed that the 90 bp insertion was
generated from the activation of cryptic splice junction
sequences located within intron 28, downstream of the
above-mentioned polyadenylation signal (GenBank
NT_029289.10, nts 8,668,121–218). Therefore, this addi-
tional SPINK5 exon has been therefore named exon 28a
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and the corresponding transcript SPINK5l (SPINK5 long)
(GenBank DQ149928).
Given that cDNA libraries often contain a range of cDNA
with anomalous structures because of cloning artifacts, the
results obtained were verified by 30 and 50 rapid amplification
of cDNA ends (RACE) using total RNA extracted from
differentiated NHK. The outcome of sequence analysis of
the cDNA fragments obtained confirmed the diversity of the
alternative transcripts in their 30-end portions (data not
shown) and showed that all SPINK5 mRNA species utilize
the same transcription start site, which is located 73 bp
upstream to the ATG codon (GenBank NT_029289.10, nt
8,606,471). Computational analysis of the nt sequence of the
50 portion of SPINK5 gene, using the Promoterscan program
(http://www.Ifti.org), further substantiated the localization of
the transcription initiation site, and showed the presence of a
TATA box 22 bp upstream of the transcription start site
(GenBank NT_029289.10, nts 8,606,449–54).
The SPINK5 alternative transcripts are not specific to NHKs
Previous studies have reported high SPINK5 transcription
levels in lymphoepithelial tissue such as the epidermis, oral
mucosa, vaginal epithelium, thymus, tonsils, and Bartolini’s
and parathyroid glands (Magert et al., 1999, 2002; Komatsu
et al., 2002). Therefore, in order to specifically evaluate the
expression pattern of the different SPINK5 mRNAs, real-time
reverse transcriptase-PCR on cDNA from several human
tissues was carried out. At first, by using a primer pair that
allowed the amplification of all SPINK5 transcripts, we
established that the SPINK5 gene displays its greatest
expression level in the skin, tongue, and esophagus (Figures
2a and b). Noticeable amounts of SPINK5 mRNAs were also
found in the tonsils, duodenum, bladder, rectum, stomach,
colon, and thymus and, to a lesser extent, in the ilocecum,
ileum, and jejunum (Figure 2b). No SPINK5 expression could
be detected in the bone marrow, lymphnode, leukocytes,
spleen, and liver. Subsequently, with primer pairs that
specifically amplify SPINK5sh and SPINK5l, we analyzed
their expression pattern (Figure 2a). By this means, we could
establish that all SPINK5 transcripts share an analogous tissue
distribution pattern, thus indicating that the SPINK5 pre-
mRNA undergoes alternative processing in all SPINK5
transcriptionally active tissues (Figure 2c and d).
The expression of SPINK5 alternative transcripts is regulated
during keratinocyte differentiation in vitro
Since several reports described a single SPINK5 transcript
form (Magert et al., 1999, Chavanas et al., 2000a), we
hypothesized that the moderate differences in size among the
SPINK5 transcripts did not allow their discrimination by
conventional Northern blot analysis. Total RNA from
proliferating and differentiated cultured NHK was therefore
allowed to extensively separate (see Materials and Methods)
and was thereafter analyzed with a probe complementary to
all SPINK5 mRNAs. As expected, the sizes of the SPINK5f-l
and SPINK5l transcripts being very similar, this analysis
resulted in the detection of two transcript bands with an
apparent molecular weight of B3.7 (corresponding to both
SPINK5f-l and SPINK5l) and B3 kb (corresponding to
SPINK5sh) in all the samples analyzed (Figure 3). In keeping
with the SPINK5/LEKTI mRNA expression in the uppermost
differentiated layers of the epidermis (Komatsu et al., 2002;
Bitoun et al., 2003), the expression level of all transcripts
significantly increased as cells differentiated, in vitro
890−915
916−941
942−955
890−915
916−941
942−967
968−985
890−915
916
a
b
c
Figure 1. Partial nucleotide sequence of SPINK5 cDNAs derived from NHK and predicted amino-acid sequences of LEKTI isoforms. (a) SPINK5f-l transcript;
(b) SPINK5sh; and (c) SPINK5l. The nucleotide sequence common to all transcript forms is in green, while the portion common only to SPINK5f-l and SPINK5l and
not present in SPINK5sh is in blue. The three novel in-frame codons of SPINK5sh are in yellow. The cryptic polyadenylation site utilized by SPINK5sh is in bold.
The 90 bp insertion of SPINK5l is in pink. The encoded amino acids are numbered from the translation initiation site. *, indicates the stop codon TAA.
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(Figure 3, lanes 1–4). Neither theB3.7 nor theB3 kb mRNAs
were visualized in NS patient cells (Figure 3, lane 5), which is
consistent with the process of nonsense-mediated mRNA
decay associated with NS mutations.
The 3.5 kb SPINK5f-l transcript is predominant in differentiated
NHK
Next, we assessed the relative amount of the three SPINK5
transcripts in differentiated NHKs by RNase protection
assays. As shown in Figure 4, significant amounts of all
transcript species are present in these cells. However,
densitometric analysis of the protected bands revealed that
the full-length transcript isB7 times more abundant than the
short transcript, while the molar ratio between SPINK5f-l and
SPINK5l is B3:1.
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Figure 2. Transcription level of SPINK5 mRNAs in different human tissues,
as determined by real time reverse-PCR. (a) Schematic representation of
SPINK5 cDNAs with the location of primers used for real-time reverse-PCR;
(b) transcription level of all SPINK5 transcripts, as determined using the
primer pair 1F–1R; (c) transcription level of SPINK5sh, as determined using the
primer pair 2F–2R; and (d) transcription level of SPINK5l, as determined using
the primer pair 2F–3R. All expression levels are relative to liver. Each value
represents the mean of three independent amplifications, with the error bars
being the standard error of the mean.
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Figure 3. Northern blot analysis of SPINK5 transcription level in prolifer-
ating and differentiated NHK and NS keratinocytes. The high-resolution
electrophoretic separation of total RNA from proliferating (lane 1) and
differentiated (lanes 2–4) NHK allows the visualization of two SPINK5
transcript bands of B3.7 and B3 kb. None of these bands was detected in
differentiated NS keratinocytes (lane 5). Cell differentiation was induced by
the addition of 1.2 mM calcium to the cell media for 24 (lane 2), 48 (lane 3),
and 72 (lanes 4 and 5) hours. Sample loading has been normalized to the
transcriptional level of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH).
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Figure 4. RNase protection assay (RPA) analysis of SPINK5 transcripts in
differentiated NHK. Lane 2: RPA with a probe able to protect SPINK5sh and
SPINK5f-l. The RNA probe used allows discrimination between the SPINK5sh
and SPINK5f-l splice variants (462 and 426 bp, respectively); lane 3: RPA with
a probe able to protect SPINK5l and SPINK5f-l generating a 490 and a 426 bp
fragment, respectively. In the latter experiments, the SPINK5f-l protected
fragment shows a migration rate lower than expected (estimated length
B440 bp). This fact could be ascribed to the almost identical base
composition between the first portion of the SPINK5l-specific riboprobe and
the SPINK5f-l transcript. Bands corresponding to the protected mRNA
fragments are indicated to the right. Sample loading has been normalized to
the b-actin transcript.
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The three LEKTI isoforms are expressed in differentiated NHK
In addition to the previously described 1,064-amino-acid
LEKTI isoform (Magert et al., 1999) (GeneBank Q9NQ38),
translation of SPINK5sh and SPINK5l transcripts is expected to
produce a shorter 916-amino-acid form and a longer
polypeptide carrying a 30 residue insertion in the linker
region between D13 and D14, respectively (Figure 5a).
However, only two glycosylated precursor forms of B145
and 125 kDa were previously detected in brefeldin A (BFA)-
treated differentiated NHKs (Bitoun et al., 2003), using
polyclonal antibodies directed against D13–D15 (a-C anti-
body), which should have recognized all LEKTI isoforms
(Figure 5a). To test whether this discrepancy could be caused
by the size similarity between the full-length protein and the
isoform harboring the 30-amino-acid insertion, total cell
extracts from BFA-treated differentiated NHK were subjected
to a high-resolution electrophoretic separation, before
Western from analysis with the a-C antibody (Bitoun et al.,
2003). Using these experimental conditions, LEKTI detection
in these cells not only showed the previously described
B145 and 125 kDa bands but also revealed a higher
molecular weight isoform (B148 kDa), consistent with a
glycosylated form of LEKTI encoded by the SPINK5l mRNA
(Figure 5b, lane 1). In keeping with our previous results,
treatment of the cell extracts with the peptide N-glycosidase F
resulted in a molecular weight shift ofB10 kDa for all protein
bands, thus confirming the glycosylated state of all LEKTI
isoforms (data not shown).
As deduced from the nt sequence of the SPINK5sh
transcript, the shorter LEKTI isoform is expected to consist
in only the first 13 inhibitory domains (D1–D13). These data
prompted us to demonstrate that the B125 kDa LEKTI lacks
the last two inhibitory domains. Thus, a novel polyclonal
antibody, directed against D14–D15 (a-D14–D15), that
should specifically recognize only the full-length protein
and the LEKTI isoform carrying the 30-amino-acid insertion
encoded by exon 28a, was generated (Figure 5a). As
compared to the results discussed above, the immunodetec-
tion of LEKTI by Western blot analysis using the a-D14–D15
polyclonal antibody did not reveal the B125 kDa band
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Figure 5. Molecular detection of LEKTI precursors and C-terminal proteolytic fragments in differentiated NHK- and CHO-transfected cells. (a) Schematic
representation of the three LEKTI isoforms, with specific regions recognized by a-C (a-D13–D15) and a-D14–D15 antibodies. a-C antibody is able to detect both
isoforms, whereas a-D14–D15 is able to detect LEKTIl and LEKTIf-l isoforms but not LEKTIsh isoform; (b) Western blot analysis of differentiated NHKs cultured
with (lanes 1 and 2) or without (lanes 3–6) BFA. Total cell extracts were analyzed using a-C (a-D13–D15) (lanes 1 and 4) and a-D14–D15 (lanes 2 and 5)
antibodies, or using the corresponding preimmune serum (lanes 3 and 6); (c) Western blot of intracellular (lanes 1–3) and extracellular (lanes 4–6) fractions of
CHO cells transiently transfected with the empty pEFDEST-51 vector () (lanes 1 and 4), pEF-DEST51-SPINK5f-l (LEKTIf-l) (lanes 2 and 5), and pEF-DEST51-
SPINK5sh (LEKTIsh) (lanes 3 and 6) with a-C antibody. The B145 and B125 kDa precursors detected in the intracellular extracts, and the B65 and B42 kDa
proteolytic forms detected in the media are indicated on the right. Note the presence of a minor band of B80 kDa in the media of both LEKTIf-l and LEKTIsh
CHO-transfected cells, probably resulting from a proteolytic process occurring specifically in these cells. The same volume of intracellular and extracellular
extracts was loaded in order to compare the protein level in each compartment. (d) Proposed model of full- and short-length LEKTI proteolysis in cultured NHKs.
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(Figure 5b, lane 2). This result strongly suggests that the
shorter LEKTI isoform detected by the a-C antibody represents
the translation product of the SPINK5sh transcript lacking D14
and D15. Finally, in differentiated NHKs in which LEKTI
intracellular cleavage was not prevented by BFA treatment,
the a-C polyclonal antibody detected three C-terminal
proteolytic fragments ofB68, 65, and 42 kDa with no larger
precursor form, while the novel a-D14–D15 polyclonal
antibody revealed only the B68 and 65 kDa bands (Figure
5b, lanes 4 and 5). This result indicates that the B42 kDa
band does not contain the LEKTI inhibitory domains D14 and
D15, and thus strongly suggests that this fragment represents
the C-terminal cleaved portion of the LEKTI shorter isoform.
Conversely, the B68 and 65 kDa bands, detected by both
antibodies, are likely to represent the C-terminal proteolytic
fragments of the B148 and 145 kDa LEKTI precursors,
respectively. None of the above-mentioned signals detected
using preimmune sera and the specificity of the bands was
further confirmed by competition experiments (data not
shown).
In order to definitely establish the identity of the LEKTI
precursors and proteolytic fragments detected in keratino-
cytes, constructions of mammalian expression vectors carry-
ing LEKTIf-l cDNA (145 kDa precursor) and short-length
cDNA (125 kDa precursor) were carried out. Chinese hamster
ovary (CHO) cells were transiently transfected with the two
recombinant vectors, and the intracellular and extracellular
extracts were analyzed by Western blot using the a-C
antibody (Figure 5c). A B145 kDa band was seen in the
intracellular extract of CHO transfected with LEKTIf-l (Figure
5c, lane 2), while a B65 kDa band was visualized in the
medium of these cells (Figure 5c, lane 5). Similarly, a
B125 kDa band was detected in the intracellular extract of
CHO transfected with LEKTI short-length (Figure 5c, lane 3),
and a 42 kDa band was seen in the medium of these cells
(Figure 5c, lane 6).
In CHO cells, it is interesting to note that LEKTI proteolytic
fragments are mostly found in the medium and are in low
abundance (B65 kDa) or absent (B42 kDa) in the intracel-
lular fraction. This result indicates that, following cleavage of
LEKTI precursors, proteolytic fragments are rapidly secreted
in the medium where no degradation products are visible,
indicating a high stability of these C-terminal fragments at
371C. All together, these results clearly demonstrate that the
C-terminal fragments originate from the proteolysis of LEKTI
precursors, and are likely to arise from the use of cleavage
sites within the same linker region (Figure 5d).
DISCUSSION
The results presented here demonstrate that, in humans,
alternative processing of the SPINK5 pre-mRNA generates
three classes of transcripts encoding three isoforms of LEKTI
differing in their COOH-terminal amino-acid sequence. The
three isoform-specific mRNAs are produced from the same
structural gene through a combination of polyadenylation site
selection during 30-end formation and alternative splicing. All
transcripts share the same transcription start site, 73 bp of
50untranslated sequence and a 2,739 bp coding sequence
corresponding to the first 28 exons. Thereafter, the splicing of
exon 28 to exon 29 generates the previously described
SPINK5f-l mRNA, which is encoded by 33 exons. A shorter
SPINK5 transcript, which contains an open reading frame of
only 2,748 bp, instead, results from the usage of an internal
polyadenylation site and of a 30-end cleavage site present
within intron 28. Finally, SPINK5l, the third mRNA species
identified, is encoded by 34 exons and contains, as compared
to the full-length transcript, a 90 bp insertion encoded by a
cryptic exon (exon 28a) located within intron 28.
Alternative splicing and utilization of intronic polyadeny-
lation signals are quite common mechanisms used to regulate
gene expression. In some instances, the production of
different forms of mRNA by controlled usage of alternatively
spliced exons or intronic polyadenylation sites constitutes a
mechanism that allows the synthesis of tissue-specific
isoforms (Liu and Johnson, 2002; Garcia-Sacristan et al.,
2005; Ule et al. 2005). In other instances, such as the
synthesis of the secreted or membrane-bound forms of
immunoglobulin m heavy chain from a single-copy gene,
the recognition and use of the intronic polyadenylation signal
is developmentally regulated as part of the maturation
process of B cells (Galli et al., 1988). In our case, through
the analysis of a wide panel of human tissues, we
demonstrated that the alternative processing of the SPINK5
pre-mRNA occurs in all SPINK5 transcriptionally active
tissues, thus excluding a tissue-specific regulated process.
Although we have no element to evaluate whether the
alternative processing of the SPINK5 pre-mRNA represents a
developmentally regulated process and establish how the
structural differences of the SPINK5 mRNAs affect mRNA
stability and/or translational efficiency, an important implica-
tion of our results is that, like many other genes, the human
SPINK5 gene is capable of producing various LEKTI isoforms
with related but distinct structures and for which, a different
function can be postulated.
Mammalian Kazal-type serine protease inhibitors are very
small proteins generally containing only one inhibitory
domain, the specificity of which depends on the nature of
the reactive amino acids. LEKTI, instead, is a long protein
composed of an extraordinarily high number of potential
bioactive domains (Magert et al., 1999). Based on the
colocalization of SPINK5 transcripts and various subtilisin-
like proprotein convertases in the granular layer of the
epidermis, intracellular processing of the inactive precursor/s
by these endoproteases has been postulated (Komatsu et al.,
2002). The number of consensus sequences for subtilisin-like
proprotein convertases cleavage identified within LEKTI
linker sequences could generate at least 14 polypeptides
(Komatsu et al., 2002). However, by transfecting the SPINK5f-l
and SPINK5sh cDNAs in mammalian CHO cells, we
demonstrated that theB65 and 42 kDa proteolytic fragments
detected in NHKs represent the C-terminal portion of the
B145 and 125 kDa LEKTI precursors, respectively. These
proteolytic fragments correspond to several domains linked
together, and are most likely originating from the same
cleavage site of the two precursors (Figure 5d). Thus, while
each linker, very rich in dibasic residues, can potentially be
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cleaved by subtilisin-like proprotein convertases, a preferen-
tially cleavage site is used in both LEKTIf-l and LEKTIsh
precursors.
Whereas single domains D1, D5, and D6 have been
isolated from human blood filtrate (Magert et al., 1999,
2002), such individual domains have not been reported so far
in cultured keratinocytes (Bitoun et al., 2003). Instead, a
30 kDa protein with an N-terminal sequence matching to D8
was purified from the medium of differentiated keratinocytes
(Ahmed et al., 2001). In our study, we found no evidence for
the presence of C-terminal small LEKTI fragment ofB10 kDa,
which could correspond to a single domain, in the media of
NHKs or transfected CHO cells. This suggests that the active
forms of LEKTI in keratinocytes include C-terminal multi-
domain fragments. This hypothesis is further supported by the
Western blotting detection of high molecular weight (B110,
90, and 60 kDa) LEKTI proteolytic fragments in human hair
roots, while no small LEKTI forms were reported in this study
(Raghunath et al., 2004).
To date, the identity of the LEKTI bioactive fragments as
well as the nature of their targeted proteinases are still largely
unknown. Many aspects of LEKTI biological functions still
remain a matter of speculation. Several findings make stratum
corneum tryptic enzyme and stratum corneum chymotryptic
enzyme the most suitable candidate targets of LEKTI. These
two enzymes are involved in the epidermal cornification and
desquamation processes as well as in hair development (Yang
et al., 2004; Descargues et al., 2005; Hewett et al., 2005).
However, the existence of other proteases regulated by LEKTI
in additional biological pathways has been postulated. Since
Spink5 null mice replicate skin and hair key pathological
features of NS, some of the LEKTI targets are most likely to be
similar in both humans and mice, and the NS mouse model
will help in elucidating their nature. Some others, instead,
might be peculiar to humans and be related to the existence
of multiple LEKTI isoforms. Indeed, although the genomic
organization and the expression pattern of the mouse SPINK5
gene are very similar to the human counterpart, this single-
copy gene encodes a sole murine LEKTI isoform. Although
lacking human LEKTI domain 6, the mouse protein shares
many structural features with the longest human isoform. In
particular, it consists in 14 domains and interspacing linker
regions and contains the 30-amino-acid insertion encoded by
exon 28a in humans. However, in humans, this exon is
alternatively spliced in or out, while in the mouse, the
corresponding exon (mouse exon 27) is constitutively
expressed (Galliano et al., 2005). Thus, the alternative
processing of the SPINK5 pre-mRNA represents a mechanism
that has arisen after mouse–human divergence. Exon recogni-
tion being strictly dependent on sequence elements residing
in the immediate vicinity of the exon–intron borders,
computational analyses of the mouse and human genomic
sequences surrounding the exon encoding the 30-amino-acid
insertion were carried out. Using an automated splice site
analyses tool (https://splice.cmg.edu), the in silico splicing
prediction showed that, as compared to the mouse exon 27,
the human exon 28a had a weaker exon definition and it
could, therefore, sometimes not be detected by the spliceo-
some machinery (Wessagowit et al., 2005). It might also be
postulated that this 30-amino-acid region is essential for
mouse LEKTI function, while it appears of less importance in
humans. This sequence does not correspond to a Kazal
domain nor to a dibasic residue-rich linker region. It is then
difficult to evaluate the biological importance of this
sequence.
Interestingly, all NS patients characterized to date at the
molecular level carry premature termination codon mutations
within the transcript region common to the three SPINK5
mRNA forms. The identification and subsequent analysis of
NS patients harboring the defect of a specific LEKTI isoform
would allow a better understanding of the multiple biological
roles of LEKTI isoform. It could be especially useful for
evaluating potential compensatory events between the three
LEKTI isoforms.
In conclusion, the results presented here highlight
the complicated regulation of LEKTI at both transcriptional
and post-transcriptional levels. This degree of comple-
xity supports a key role of this Kazal-type inhibitor in
skin biology and raises the question of the specific function
of each isoform in the skin and other LEKTI-expressing
tissues.
MATERIALS AND METHODS
Materials
All reagents and chemicals were purchased from Sigma (Milan, Italy
and Toulouse, France), unless otherwise stated. Cell culture media
were obtained from Invitrogen (Milan, Italy and Toulouse, France).
Cell culture
Normal and NS human primary keratinocytes were isolated and
cultured as described previously (Bitoun et al., 2003). CHO cells
were grown in Dulbecco’s modified Eagle’s Medium supplemented
with 10% fetal calf serum, and 100 U/ml penicillin/streptomycin.
BFA and peptide N-glycosidase F keratinocyte treatments have been
described before (Bitoun et al., 2003).
RNA extraction, reverse transcriptase-PCR, and cDNA probes
Total RNA, extracted by lysis of differentiated NHK cultures in the
presence of guanidine isothiocyanate, was reverse-transcribed using
the SuperScript RNase H free reverse transcriptase and random
hexamers (Invitrogen, Carlsbad, CA). The cDNA product was then
used as a template for PCR amplifications using specific oligonu-
cleotides. To amplify the 660 bp region of SPINK5 cDNA comprising
nts 1,799–2,458 (GenBank NM_006846), PCR conditions were as
described below with an annealing temperature of 601C, and
primers used were as follows: 50-GATCCTATTGAGGGTCTAGAT-30
and 50-ATTACCATGTGTCTTGCCATC-30. To produce the 280 bp
probe specific for the B3.5 kb mRNA, the following primers were
used: 50-CAGGAAGATTGTTGAAAGCCAT-30 and 50-ATTGAA
CAGGCAGTTGGACAG-30, which amplify part of the SPINK5f-l
transcript 30untranslated region (GenBank NM_006846, nts
3,239–3,511). PCR cycling conditions were: 941C for 10 minutes,
35 cycles comprising 941C for 30 seconds, 581C for 45 seconds, and
721C for 1 minute followed by a final extension at 721C for
10 minutes. All probes were 32P-labeled using the random priming
kit (Amersham Biosciences Europe, Cologno Monzese, Italy).
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cDNA library screening
The SPINK5 open reading frame probe encompassing nt
1,799–2,458 was used to screen 1 106 clones from a l ZAP
differentiated NHK cDNA library (kindly provided by E. Di Marco,
Genova, Italy). Library screening, isolation, and purification of
positive clones were performed according to standard protocols. The
selected cDNA inserts were then analyzed by automated nt
sequencing (ABI PRISM, 377 DNA Sequencer, Perkin-Elmer Life
and Analytical Science, Milan, Italy).
50- and 30-RACE
The existence of three distinct SPINK5 transcripts in differentiated
NHK was further investigated by 30-RACE experiments. As target,
2mg of total RNA from differentiated NHKs were reverse transcribed
and amplified using the 50/30-RACE kit, second generation (Roche
Applied Science, Monza, Italy), following the manufacturer’s
protocol. The SPINK5-specific sense primer used was 50-TGCAG-
GACATGGTTCCAGTG-30 (GenBank NM_006846, nts 2,113–
2,132).
To determine the start site of transcription of the three SPINK5
transcripts, 50-RACE analysis, using antisense primers specific for
each transcript, was carried out. Specifically, to determine the
transcription start site of the B3.5 kb mRNA, the antisense primer
50-CTGCACTCATCCTTTGCATTA-30 (GenBank NM_006846, nts
2,773–2,793), which spans the junction between exons 28 and 29
on exons 28 and 29, was used. To analyze the shorter transcript
50-end, the antisense primer was 50-GTAAAATGGTTATTTTGG
TATC-30, corresponding to its 30untranslated region (GenBank
NT_029289.10, from nts þ 16 to þ 36 of SPINK5 intron 28).
Finally, to ascertain the transcription start site of the SPINK5
transcript carrying the exon 28a insertion, the antisense primer was
50-CTGAACCTGTCTGCACTGGTC-30 (GeneBank NT_029289.10,
from nts þ 687 to þ 707 of SPINK5 intron 28).
All cDNA products, tailed as depicted by the manufacturer
(Roche Applied Science), were amplified using a SPINK5 reverse
primer 50-CTTACTGGCAGCATCTTGTATG-30 placed between the
first two exons (GenBank NM_006846, nts 91–112). The resulting 50-
RACE products were purified on an agarose gel, ligated into the
plasmid vector pCR II Topo TA vector (Invitrogen), and sequenced.
Northern blot and real-time reverse transcriptase-PCR
To allow electrophoretic separation of the SPINK5 transcripts, 20mg
of total RNA from normal and NS differentiated NHKs were
fractionated for 18 hours on a 1.2%. agarose/formaldehyde gel,
transferred to Hybond Nþ nylon membranes (Amersham Bios-
ciences). Visualization of all transcripts was achieved using the same
radiolabeled probe used for library screening (nts 1,799–2,458). To
assess uniformity of RNA loading and transfer, membranes were
further hybridized with a probe corresponding to the ubiquitously
expressed gene glyceraldehyde-3-phosphate dehydrogenase
(GenBank NM002046). Quantification of the hybridization signals
was performed by densitometric scanning using the GS-750
densitometer (BioRad Laboratories, Hercules, CA).
To evaluate the transcription level of the three SPINK5 transcripts
in different human organs, real-time reverse transcriptase-PCR was
performed using an ABI PRISM 7000 instrument (Perkin-Elmer Life
and Analytical Science). Templates were: Human Digestive and
Human Immune System MTCTM cDNA Panels (BD Biosciences,
Milan, Italy) and human skin, tongue, and bladder cDNAs
synthesized from polyAþ RNA (BD Biosciences). Relative quantifi-
cation of SPINK5 mRNAs was performed using the SYBRs Green
PCR Master Mix (Applied Biosystem, Foster City, CA), following the
manufacturer’s instructions. To evaluate the expression level of all
SPINK5 transcripts, the primers used were SPINK5 1F 50-GACATC
TAAGAGTACAGCTTCCTT-30 and SPINK5 1R 50-TGTTGCCATG
CATTTTCCCATCTG-30, which are located on exons 14 and 15,
respectively. For the amplification of SPINK5sh and SPINK5l, the
same oligonucleotide, SPINK5 2F 50-TGTCAGAGCATCTTTGATC
GAGA-30 located on exon 28, was used in combination with the
primer SPINK5 2R 50 AAGCTGGAGAAGAATGCAAAATTC 30
located on the 30untranslated region region of the short transcript,
or with the oligonucleotide SPINK5 3R 50-GAACCTGTCTG
CACTGGTCCTT-30, which lies within exon 28a, respectively. All
primer pairs were designed in order to minimize the possibility of
genomic DNA amplifications. All reactions were normalized to
glyceraldehyde-3-phosphate dehydrogenase, which was detected
using primers 50-GAAGGTGAAGGTCGGAGTC-30 and 50-GAA
GATGGTGATGGGATTTC-30 and quantification was performed
using the comparative CT method (Pfaffl, 2001). For each SPINK5
transcript, three independent amplifications were carried out. A
nontemplate control was run with every assay and all determinations
were performed in duplicate to achieve reproducibility.
RNase protection assay
Five micrograms of total RNA from differentiated NHKs and cultured
human fibroblasts, as negative control, were hybridized overnight
with specific radiolabeled riboprobes, treated with RNase A, RNase
T1, and proteinase K, and analyzed on a polyacrylamide gel, as
described (Micheloni et al., 2002).
To generate the SPINK5sh transcript-specific riboprobe, the
following oligonucleotide primers, forward 50-GATACATGTGAT
GAGTTTAGAA-30 (GenBank NM_006846, nts 2,357–2,378) and
reverse 50-GTAAAATGGTTATTTTGGTATC-30 (GeneBank AC
008722, from nts þ 16 to þ 36 of SPINK5 intron 28), were used
to amplify from human genomic DNA a 462 bp fragment encom-
passing exons 25–28 and the first 36 bp of intron 28. The PCR
fragment, inserted in the dual promoter pCR II Topo TA vector
(Invitrogen, San Giuliano Milanese, Milan, Italy), was subjected to in
vitro transcription using the Sp6 and T7 RNA polymerases (Promega
Corporation, Madison, WI) in the presence of [32P]UTP (Amersham
Biosciences). The antisense product obtained allowed the discrimi-
nation between the short and the full-length transcripts (462 and
426 bp, respectively). The SPINK5 riboprobe specific for the splice
variant carrying the exon 28a insertion was produced by using the
same forward primer as above and the reverse primer 50-
AGGAACGCCCAGGTTGTC-30 (GenBank NT_029289.10, from nts
733–750 of SPINK5 intron 28), which amplified from NHK cDNA a
490 bp fragment spanning exons 25–28 and the first 64 bp of exon
28a. The RNA probe, generated by transcription of the PCR-cloned
fragment, produces on SPINK5f-l and SPINK5l a 426 and 490 bp
protected fragment, respectively. The length of the protected RNA
bands was estimated using radiolabeled RNA molecular weight
markers (Roche Applied Science). To verify equal sample loading, a
160 bp b-actin riboprobe was used. Relative intensity of bands on
autoradiograms was quantified using a GS-670 densitometer (Biorad
Laboratories).
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Anti D14–D15–LEKTI polyclonal antibody production
The SPINK5 cDNA fragment encoding the protein domains
D14–D15 (nts 2,781–3,241) was amplified by PCR using the forward
primer 50-CGGGATCCAGGATGAGTGCAGTGAAT-30 and the D15
antisense primer (Bitoun et al., 2003). PCR cycling conditions were
941C for 10 minutes, 35 cycles comprising 941C for 30 seconds,
551C for 45 seconds, and 721C for 1 minutes, followed by a final
extension at 721C for 10 minutes. The amplified cDNA product,
analyzed by direct sequencing, was subcloned into the glutathione-
S-transferase gene fusion vector pGEX-3X (Amersham Biosciences)
using the EcoRI/BamHI restriction sites. The recombinant vector was
then transformed into competent TOP10 E. coli cells (Stratagene,
Amsterdam, The Netherlands), and selected clones were checked by
DNA sequencing. Expression and purification of the glutathione-S-
transferase–D14–D15 fusion protein were essentially performed as
described previously (Bitoun et al., 2003). Immunization of rabbits
with the recombinant antigen glutathione-S-transferase–D14–D15
was performed by Primm (Milan, Italy) and crude antiserum was
purified by affinity chromatography, using the AminoLink Plus
Immobilization Trial purification procedure (Pierce, Rockford, IL),
was performed following the manufacturer’s instructions. The
antibodies were termed a-D14–D15.
Western blotting
Protein sample quantification and LEKTI detection with a-C (a-LEKTI
D13–D15) polyclonal antibodies were carried out, as described
(Bitoun et al., 2003). LEKTI polyclonal a-D14–D15 antibodies were
used at the final concentration of 1 mg/ml. To allow electrophoretic
separation of the B148/145 kDa LEKTI isoforms, protein samples
from BFA-treated cell lysates were fractionated on a 5% SDS-PAGE
(Biorad Laboratories). To test the signal specificity, competition
experiments were performed as described previously (Bitoun et al.,
2003).
Cloning of LEKTI cDNAs into pEF-DEST51 expression vector
LEKTIf-l cDNA (GenBank NM_006846) and short-length cDNA
(GenBank DQ149929) were amplified by long-range PCR (PfU
Turbo, Stratagene, Milan, Italy) from a vector containing the full-
length cDNA as a template. The PCR products were subcloned into
the pDEST8 vector by homologous recombination and transferred
into the mammalian expression vector pEF-DEST51 using the
Gateway technology, according to the manufacturer’s instructions
(Invitrogen). pEF-DEST51-LEKTI and pEF-DEST51-LEKTIsh constructs
were fully sequenced using the Big Dye Terminator Sequencing Kit
and an ABI 3100 automated sequencer (Applied Biosystem).
CHO cell transfections
One day prior to transfection, CHO cells were plated at 5 104 cells
per well of a six-well plate. The day of the transfection, cells at 70%
confluence were transiently transfected with 1mg of pEF-DEST51,
pEF-DEST51-LEKTI, or pEF-DEST51-LEKTIsh plasmid DNA, using the
FuGENETM 6 Transfection Reagent, according to the manufacturer’s
recommendations (Roche Applied Science). Twenty-four hours after
transfection, medium was replaced with serum-free medium and
cells were maintained in culture for an additional 24 hours. Both
intracellular and extracellular protein extracts were prepared for
Western blot analysis. Cells were lysed in a solution containing Tris-
Cl 50 mM, pH 8, 150 mM NaCl, EDTA 5 mM, pH 8, 1% NP40, 1 mM
phenylmethylsufonyl fluoride, 10 mg/ml leupeptine, 10 mg/ml pep-
statin A, 1 mg/ml antipaı¨ne. Lysates were clarified from insoluble
material by centrifugation at 13,000 g, 41C for 5 minutes. The
conditioned medium was concentrated by overnight acetone
precipitation. Proteins were recovered by centrifugation at
13,000 g, 41C for 30 minutes and resuspended in 30ml of the lysis
buffer. Proteins were quantified by Bradford protein assay kit (Biorad
Laboratories).
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